Clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD) - Scientific guideline

This document provides guidance on the evaluation of new medicinal products for the treatment of attention deficit hyperactivity disorder with focus on the childhood onset.

Keywords: Attention deficit hyperactivity disorder (ADHD), children, adults, psychostimulants

Current effective version

Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)

Adopted Reference Number: EMEA/CHMP/EWP/431734/2008 Rev. 2 Corrigendum

Document history

Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)

Adopted Reference Number: EMEA/CHMP/EWP/431734/2008 Rev. 2 Corrigendum

Overview of comments received on 'Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)' (EMEA/CHMP/EWP/431734/2008)

Adopted Reference Number: EMEA/CHMP/EWP/431734/2008

Draft guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)

Draft: consultation closed Reference Number: EMEA/CHMP/EWP/431734/2008

Draft concept paper on development of guideline on the treatment of attentional deficit hyperactivity disorder (ADHD)

Draft: consultation closed Reference Number: EMEA/CHMP/EWP/20119/2008